Drug intelligence / Profile preview

EVM18

Development stage: Preclinical
Lead developer: Everest Medicines
Administration: Intravenous

Overview

EVM18 is an early-stage therapeutic candidate being developed in-house by Everest Medicines (also known as Genting Pharmaceutical in Suzhou). It is currently in the Pre-IND (Investigational New Drug) stage, with ongoing or planned Investigator-Initiated Trials (IIT). The drug is being explored for applications in oncology and immunology. Specific details regarding its molecular modality (e.g., small molecule, monoclonal antibody) and biological target have not been publicly disclosed by the sponsor as of the latest pipeline updates.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on EVM18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVM18.

Explore the full profile